Ligand Pharmaceuticals (LGND) Cash from Investing Activities (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Cash from Investing Activities data on file, last reported at -$94.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 2027.81% year-over-year to -$94.3 million; the trailing twelve-month figure through Mar 2026 stood at -$476.6 million (down 253.02% YoY), and the FY2025 full-year result was -$377.3 million, down 162.64% from the prior year.
• Cash from Investing Activities eased to -$94.3 million in Q1 2026, from -$18.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $113.9 million in Q1 2022 to a low of -$353.4 million in Q3 2025.
• A 5-year average of -$27.3 million and a median of -$10.3 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 229.64% in 2025 and sank 2027.81% in 2026, its largest moves.
• Tracing LGND's Cash from Investing Activities over 5 years: stood at -$7.3 million in 2022, then tumbled by 41.19% to -$10.3 million in 2023, then tumbled by 275.56% to -$38.6 million in 2024, then soared by 53.13% to -$18.1 million in 2025, then slumped by 421.14% to -$94.3 million in 2026.
• Business Quant data shows LGND's Cash from Investing Activities at -$94.3 million in Q1 2026, -$18.1 million in Q4 2025, and -$353.4 million in Q3 2025.